Skip to main content
Erschienen in: Rheumatology International 8/2005

01.10.2005 | Case Report

Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil

verfasst von: Douglas E. Gladstone, Marc G. Golightly, Kenneth W. Zamkoff

Erschienen in: Rheumatology International | Ausgabe 8/2005

Einloggen, um Zugang zu erhalten

Excerpt

Mediated by cold-precipitating immunoglobulins, necrotizing vasculitis can result in multiple organ system dysfunction and failure. Classified into three subtypes in 1974 by Brouet et al. [1] these cryoglobulins are associated with malignancy, autoimmunity, and viral infection. Eight years earlier, Meltzer et al. [2] described essential mixed cryoglobulinemia to denote autonomous disease. The mixed cryoglobulinemia syndrome characterized by purpura, weakness, and arthralgias, may result pathologically in chronic hepatitis, membranoproliferative glomerulonephritis, peripheral neuropathy, and skin ulceration. Initial interventions for symptomatic essential mixed cryoglobulinemia are immunosuppression with steroids and cyclophosphamide with or without plasmapheresis/plasma exchange [3]. …
Literatur
1.
Zurück zum Zitat Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–788 Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–788
2.
Zurück zum Zitat Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966) Cryoglobulinemia—a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40:837–856 Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966) Cryoglobulinemia—a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40:837–856
3.
Zurück zum Zitat Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins. J Clin Pathol 55:4–13PubMed Ferri C, Zignego AL, Pileri SA (2002) Cryoglobulins. J Clin Pathol 55:4–13PubMed
4.
Zurück zum Zitat Luqmani RA, Bacon PA, Moots RJ, Janssen B A, Pall A, Emery P, Savage C, Adu D (1994) Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Qjm 87:671–678PubMed Luqmani RA, Bacon PA, Moots RJ, Janssen B A, Pall A, Emery P, Savage C, Adu D (1994) Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Qjm 87:671–678PubMed
5.
Zurück zum Zitat Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R (2003) 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin Oncol 30:243–247 Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R (2003) 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin Oncol 30:243–247
6.
Zurück zum Zitat Eugui EM, Mirkovich A, Allison AC (1991) Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23:15–18 Eugui EM, Mirkovich A, Allison AC (1991) Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 23:15–18
7.
Zurück zum Zitat Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J (2002) Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 21:282–285 Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J (2002) Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 21:282–285
Metadaten
Titel
Severe, refractory type II essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil
verfasst von
Douglas E. Gladstone
Marc G. Golightly
Kenneth W. Zamkoff
Publikationsdatum
01.10.2005
Erschienen in
Rheumatology International / Ausgabe 8/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0577-3

Weitere Artikel der Ausgabe 8/2005

Rheumatology International 8/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.